Skip to content

Treatment of cervical disorders with cervical plates and cages and to study improvement in cervical pain.

A Prospective, Single Arm, Post Market Clinical Follow-up (PMCF) Study to Evaluate the Safety and Performance of Cervical System - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/074836
Enrollment
60
Registered
2024-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M479- Spondylosis, unspecified

Interventions

Intervention1: Cervical plate and cage system: Study participants will be followed at 6 week, 6 month and 12 month. Control Intervention1: NIL: NIL

Sponsors

Auxein Medical Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting to Orthopaedic OPD/emergency, requiring treatment with anterior cervical plate or/and cage.Specific indications include: 1. Single level tuberculosis 2. Cervical mylopathy 3. Tumor 4. Trauma 5. Single level degenerative disc disease

Exclusion criteria

Exclusion criteria: 1. Patients with active local or systemic infection. 2. Patients with morbid obesity BMI more than 35 kg/m2. 3. Patients with mental disorders or currently on psychiatric treatment. 4. Alcoholics and or drug abusers. 5. Patients with metabolic bone disease. 6. Severe osteopenia 7. Metal sensitivity or allergies 8. Pregnant women or those planning pregnancy during study.

Design outcomes

Primary

MeasureTime frame
1. Radiological evaluation by X - rays to calculate meantime to achieve deformity correction/bone fusion. 2. Follow-up of the patient’s recovery by analyzing Visual analogue scale (VAS) for pain assessment.Timepoint: 6 week, 6 month, and 12 month

Secondary

MeasureTime frame
1. Improvement in quality of life through Neck disability index (NDI). 2. Evaluation of safety of device by record of any adverse event, serious adverse event.Timepoint: 6 week, 6 month, and 12 month

Countries

India

Contacts

Public ContactMr Gaurav Luthra

Auxein Medical Private Limited

clinical2@auxeinmedical.com7419066141

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026